secwatch.observer — SEC 8-K summary
======================================

Issuer:     Passage BIO, Inc. (PASG)
CIK:        0001787297
Form:       8-K
Filed at:   2024-09-06T23:59:59+00:00
Accession:  0001558370-24-012654
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 2.06
LLM model:  deepseek-v4-flash:cloud@v2

Passage Bio expects $3.5M-$5.5M impairment charge on sublease of lab space
--------------------------------------------------------------------------

- Subleased 3,200 sq ft (5% of 62,000 sq ft lab) in Hopewell, NJ; term Sept 2024 to Sept 2029, option to extend to 2032.
- Expects pre-tax impairment of $3.5M-$5.5M in Q3 2024 for ROU assets, leasehold improvements, and lab equipment.
- Impairment is non-cash; cash runway to fund operations through Q2 2026 unchanged.
- Annual sublease rent ~$0.1M (escalates 2.5%/yr); expected to reduce GAAP net loss by $0.1-$0.2M annually.
- Company pursuing additional subleases to further offset lease obligations from prior corporate developments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787297/000155837024012654/0001558370-24-012654-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787297/000155837024012654/pasg-20240904x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-012654

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer